Your browser doesn't support javascript.
loading
Outcomes for Patients With Acute Promyelocytic Leukemia in South Africa.
Shein, Rory; Mashigo, Nomusa; du Toit, Cecile E; Oosthuizen, Jenna; Seftel, Matthew D; Louw, Vernon J; Verburgh, Estelle.
Afiliación
  • Shein R; Division of Haematology, Department of Medicine, University of Cape Town and Groote Schuur Hospital, Cape Town, South Africa.
  • Mashigo N; Division of Haematological Pathology, University of Cape Town and National Health Laboratory Service, Groote Schuur Hospital, Cape Town, South Africa.
  • du Toit CE; Division of Haematology, Department of Medicine, University of Cape Town and Groote Schuur Hospital, Cape Town, South Africa.
  • Oosthuizen J; Division of Haematology, Department of Medicine, University of Cape Town and Groote Schuur Hospital, Cape Town, South Africa.
  • Seftel MD; Division of Hematology, Department of Medicine, University of British Columbia, Vancouver, British Columbia, Canada.
  • Louw VJ; Division of Haematology, Department of Medicine, University of Cape Town and Groote Schuur Hospital, Cape Town, South Africa.
  • Verburgh E; Division of Haematology, Department of Medicine, University of Cape Town and Groote Schuur Hospital, Cape Town, South Africa. Electronic address: estelle.verburgh@uct.ac.za.
Clin Lymphoma Myeloma Leuk ; 21(4): e348-e352, 2021 04.
Article en En | MEDLINE | ID: mdl-33526402
ABSTRACT

BACKGROUND:

The characteristics and outcomes of patients with acute promyelocytic leukemia (APL) from sub-Saharan Africa have not been published. PATIENTS AND

METHODS:

We report retrospectively on consecutively diagnosed APL patients treated in Cape Town, South Africa, during 1998-2019. A total of 69 patients were treated, of whom 27 (39%) were classified as having high risk APL.

RESULTS:

Early death rates at 7 and 30 days were 7% and 13%, respectively, including 4 patients who died before any treatment could be administered. Overall survival at 3 years was 76.5% (95% confidence interval, 63.9-85.2) for the entire cohort, and 82.5% (95% confidence interval, 69.7-90.2) if patients who died within 7 days of diagnosis were excluded. For 13 patients (18.8%), there was a delay of 5 or more days from time of initial presentation at a peripheral hospital until arrival at the leukemia center and administration of all-trans retinoic acid; only 1 of these patients died within 30 days.

CONCLUSION:

Despite the challenges faced in the public healthcare system of a developing country, outcomes of APL patients treated at our center are similar to outcomes from developed countries.
Asunto(s)
Palabras clave

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Tretinoina / Leucemia Promielocítica Aguda / Protocolos de Quimioterapia Combinada Antineoplásica Tipo de estudio: Diagnostic_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Adolescent / Adult / Humans / Male / Middle aged País/Región como asunto: Africa Idioma: En Revista: Clin Lymphoma Myeloma Leuk Asunto de la revista: NEOPLASIAS Año: 2021 Tipo del documento: Article País de afiliación: Sudáfrica

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Tretinoina / Leucemia Promielocítica Aguda / Protocolos de Quimioterapia Combinada Antineoplásica Tipo de estudio: Diagnostic_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Adolescent / Adult / Humans / Male / Middle aged País/Región como asunto: Africa Idioma: En Revista: Clin Lymphoma Myeloma Leuk Asunto de la revista: NEOPLASIAS Año: 2021 Tipo del documento: Article País de afiliación: Sudáfrica
...